source
- AI becomes core to biopharma R&D, driving efficiency and faster drug developmentAI is now regarded as essential to everyday operations in the biopharma sector, helping to reduce the time and cost of drug development. Pfizer CEO Albert Bourla said AI played a key role in integ…
- Amgen's Dazodalibep Shows Positive Results in First Phase 3 Trial for Sjögren’s SyndromeAmgen announced that its experimental drug dazodalibep, acquired through the Horizon Therapeutics acquisition, met the primary endpoint in the first of two Phase 3 trials for Sjögren’s syndrome, a…